BIOMAT Database Logo BIOMAT Database Logo

Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. 1991

W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
Department of Neurology, University of Kansas Medical Center, Kansas City 66103.

Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.

UI MeSH Term Description Entries
D007785 Lactose A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry. Anhydrous Lactose,Lactose, Anhydrous
D008297 Male Males
D008747 Methylcellulose Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative. BFL,Celevac,Cellothyl,Cellulone,Citrucel,Cologel,Dacryolarmes,Methocel,Methyl Cellulose,Muciplasma,Cellulose, Methyl
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
June 1991, Clinical neuropharmacology,
W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
A double-blind controlled study of MK-486 in Parkinson's disease.
January 1973, Transactions of the American Neurological Association,
W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
[Cinarizine and Parkinson's disease. Double-blind placebo-controlled study].
January 1986, Neurologia (Barcelona, Spain),
W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
January 1985, Clinical neuropharmacology,
W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
December 1970, Neurology,
W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
December 1970, Neurology,
W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
December 2000, Journal of the American Geriatrics Society,
W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.
May 2001, Movement disorders : official journal of the Movement Disorder Society,
W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
Effect of oral calcium supplementation on blood pressure in patients with previously untreated hypertension: a randomised, double-blind, placebo-controlled, crossover study.
February 1993, Journal of human hypertension,
W C Koller, and G A Block, and J E Ahlskog, and S Ahrens, and J M Cedarbaum, and G Cyhan, and C G Goetz, and P A LeWitt, and C Liss, and L McLean
Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study.
February 1986, Neurology,
Copied contents to your clipboard!